Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population

[1] de Alava E(1998)EWS-FL1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma J Clin Oncol 16 1248-1255

[2] Kawai A(2000)Prognostic factors in nonmetastatic Ewing’s sarcoma adjuvant chemotherapy: analysis of 359 patients at the Instituto Ostopedico Rizzoli J Clin Oncol 18 4-11

[3] Healey JH(1993)Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma J Clin Oncol 11 1482-1488

[4] Fligman I(1990)Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: Intergroup study IESS-II J Clin Oncol 8 1514-1524

[5] Meyers PA(1999)Ewing’s sarcoma: prognosis and survival in Mexican children from a single institution Pediatr Hematol Oncol 16 519-523

[6] Huvos AG(2000)Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing’s sarcoma study group J Clin Oncol 18 3108-3114

[7] Gerald WL(2004)VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors Am J Clin Oncol 27 529-534

[8] Jhanwar SC(2003)Addition of ifosfamide and etoposide to standard chemotherapy for Ewing ‘s sarcoma and primitive neuroectodermal tumor of bone N Engl J Med 348 694-701

[9] Argani P(1999)Comparative frequency of bone sarcomas among different racial group Chin Med J 112 1101-1104

[10] Antonescu CR(2002)Localised Ewing sarcoma/PNET of bone prognostic factors and international data comparison Med Pediatr Oncol 39 586-593

[1] de Alava E(1998)EWS-FL1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma J Clin Oncol 16 1248-1255

[2] Kawai A(2000)Prognostic factors in nonmetastatic Ewing’s sarcoma adjuvant chemotherapy: analysis of 359 patients at the Instituto Ostopedico Rizzoli J Clin Oncol 18 4-11

[3] Healey JH(1993)Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma J Clin Oncol 11 1482-1488

[4] Fligman I(1990)Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: Intergroup study IESS-II J Clin Oncol 8 1514-1524

[5] Meyers PA(1999)Ewing’s sarcoma: prognosis and survival in Mexican children from a single institution Pediatr Hematol Oncol 16 519-523

[6] Huvos AG(2000)Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing’s sarcoma study group J Clin Oncol 18 3108-3114

[7] Gerald WL(2004)VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors Am J Clin Oncol 27 529-534

[8] Jhanwar SC(2003)Addition of ifosfamide and etoposide to standard chemotherapy for Ewing ‘s sarcoma and primitive neuroectodermal tumor of bone N Engl J Med 348 694-701

[9] Argani P(1999)Comparative frequency of bone sarcomas among different racial group Chin Med J 112 1101-1104

[10] Antonescu CR(2002)Localised Ewing sarcoma/PNET of bone prognostic factors and international data comparison Med Pediatr Oncol 39 586-593